Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on January 16, 2013, covering events occurring on January 14, 2013. The filing primarily addresses the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes rather than financial performance.
Material Changes
The material change reported is the appointment of Mr. Victor Vaughn as Senior Vice President of Sales, effective January 14, 2013. Mr. Vaughn brings significant experience from Shire Pharmaceuticals, Fujisawa, and SmithKline Beecham.
Compensation and Management Commentary
Management has outlined the following compensatory arrangements for Mr. Vaughn:
- Base Salary: $275,000 annually.
- Target Bonus: 30% of annual base salary, prorated for 2013.
- Equity Grant: Options to purchase 85,000 shares of common stock, vesting equally over four years.
- Relocation Benefits: Reimbursement for travel and residence rental expenses up to $20,000 annually for the first two years and $15,000 annually for the next three years, capped at $85,000 total.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 85,000 stock options granted to Mr. Vaughn.
- Confirm the total potential cash compensation including the prorated bonus for the remainder of 2013.
- Review the attached Press Release (Exhibit 99.1) for additional strategic context regarding the sales organization.